Nonalcoholic steatohepatitis, or NASH, is one of the most common causes for liver transplants in the U.S. and Europe but there are currently no medicines approved to treat it. In this video, Nick Kenny, Syneos Health Chief Scientific Officer, is joined by Rob Riccio, PhD, Vice President of Clinical Development, Hans-Juergen Gruss, Vice President Clinical Development, and Marta Lamberton, Senior Project Director, General Medicine to discuss the progress being made to accelerate the clinical development and commercialization of new therapies for patients with NASH.
